Correction: Nanosphere Eyes FDA OK for Plavix Metabolism, Troponin Tests | GenomeWeb

The story has been updated to correct revenue estimates Nanosphere's CFO provided at the conference for tests in the company's pipeline.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nanosphere CFO Roger Moody told investors Wednesday at the 2011 Jefferies Global Healthcare Conference that the company has filed for US marketing clearance for a companion diagnostic test for assessing Plavix (clopidogrel) metabolism.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.